Ocular Therapeutix (OCUL) Profit After Tax (2013 - 2026)
Ocular Therapeutix's quarterly Profit After Tax came in at -$88.6 million in Q1 2026, down 38.34% year-on-year from -$143.7 million in Q1 2025, and down 37.06% quarter-over-quarter from -$64.7 million in Q4 2025.
Ocular Therapeutix has reported Profit After Tax for 14 years, with the latest figure at -$88.6 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 38.34% year-over-year to -$88.6 million; the trailing twelve-month figure through Mar 2026 stood at -$290.5 million (down 50.74% YoY), and the FY2025 full-year result was -$265.9 million, down 37.43% from the prior year.
- Profit After Tax for Q1 2026 stood at -$88.6 million, down from -$64.7 million in the prior quarter.
- The five-year high for Profit After Tax was -$516000.0 in Q3 2023, with the low at -$88.6 million in Q1 2026.
- Average Profit After Tax over 5 years is -$41.2 million, with a median of -$36.5 million recorded in 2024.
- Year-over-year, Profit After Tax jumped 97.87% in 2023 and plunged 6972.29% in 2024.
- Tracing OCUL's Profit After Tax over 5 years: stood at -$15.5 million in 2022, then sank by 88.01% to -$29.2 million in 2023, then tumbled by 65.6% to -$48.4 million in 2024, then slumped by 33.62% to -$64.7 million in 2025, then plunged by 37.06% to -$88.6 million in 2026.
- The last three Profit After Tax figures came in at -$88.6 million (Q1 2026), -$64.7 million (Q4 2025), and -$69.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -88.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.61 Mn |
| Dec 31, 2025 | -64.65 Mn |
| Sep 30, 2025 | -69.42 Mn |
| Jun 30, 2025 | -67.81 Mn |
| Mar 31, 2025 | -64.05 Mn |
| Dec 31, 2024 | -48.39 Mn |
| Sep 30, 2024 | -36.49 Mn |
| Jun 30, 2024 | -43.78 Mn |
| Mar 31, 2024 | -64.85 Mn |
| Dec 31, 2023 | -29.22 Mn |
| Sep 30, 2023 | -516,000.00 |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -30.32 Mn |
| Dec 31, 2022 | -15.54 Mn |
| Sep 30, 2022 | -24.19 Mn |
| Jun 30, 2022 | -18.77 Mn |
| Mar 31, 2022 | -12.54 Mn |
| Dec 31, 2021 | -3.85 Mn |
| Sep 30, 2021 | 2.66 Mn |
| Jun 30, 2021 | -8.48 Mn |
| Mar 31, 2021 | 3.12 Mn |
| Dec 31, 2020 | -85.61 Mn |
| Sep 30, 2020 | -11.94 Mn |
| Jun 30, 2020 | -36.57 Mn |
| Mar 31, 2020 | -21.51 Mn |
| Dec 31, 2019 | -26.02 Mn |
| Sep 30, 2019 | -18.78 Mn |
| Jun 30, 2019 | -24.45 Mn |
| Mar 31, 2019 | -17.12 Mn |
| Dec 31, 2018 | -17.40 Mn |
| Sep 30, 2018 | -15.01 Mn |
| Jun 30, 2018 | -13.80 Mn |
| Mar 31, 2018 | -13.77 Mn |
| Dec 31, 2017 | -13.10 Mn |
| Sep 30, 2017 | -15.57 Mn |
| Jun 30, 2017 | -18.69 Mn |
| Mar 31, 2017 | -16.02 Mn |
| Dec 31, 2016 | -12.82 Mn |
| Sep 30, 2016 | -9.60 Mn |
| Jun 30, 2016 | -11.45 Mn |
| Mar 31, 2016 | -10.84 Mn |
| Dec 31, 2015 | -10.64 Mn |
| Sep 30, 2015 | -11.52 Mn |
| Jun 30, 2015 | -10.01 Mn |
| Mar 31, 2015 | -7.58 Mn |
| Dec 31, 2014 | -7.95 Mn |
| Sep 30, 2014 | -7.29 Mn |
| Jun 30, 2014 | -6.39 Mn |
| Mar 31, 2014 | -7.01 Mn |
| Dec 31, 2013 | -3.51 Mn |
| Sep 30, 2013 | -3.52 Mn |
| Jun 30, 2013 | -3.09 Mn |